logo-loader
viewAnalytica Ltd

Analytica expands clinical indication for its unique pelvic floor exercise technology

PeriCoach system is now indicated for urinary incontinence, sexual wellness and pelvic organ prolapse.

PeriCoach System demostration
No other system on the market has this capability

Analytica Limited (ASX:ALT) has received clearance from the Australian Therapeutic Goods Administration for the expanded clinical indication for its PeriCoach System to assist in the conservative treatment of Pelvic Organ Prolapse (POP).

The PeriCoach system with its patent protected force sensing technology assists women to properly perform pelvic floor exercises.

The expanded clinical indication for PeriCoach now includes targeted resolution of symptoms for mild to moderate POP, urinary incontinence and sexual wellness.

Pelvic organ prolapse is a common and serious condition

Data suggests that 50% of women that have given birth have some degree of POP and half of women over 50 complain of prolapse symptoms.

Estimates state women have a lifetime risk of up to 12% of undergoing a surgical intervention, with a re-operation rate of nearly 20%.

Each surgical intervention in the U.S. is estimated to cost between USD$10,000- USD$20,000.

As the population continues to age and awareness of the condition grows, it is projected that the number of women with POP will increase up to 46%.

Potential sale of the technology to a multinational

Analytica chairman Dr Michael Monsour said: “This clearance from the TGA is significant in that the PeriCoach system is indicated for the most common conditions stemming from a weak pelvic floor: urinary incontinence, sexual wellness, and pelvic organ prolapse.

“No other system on the market has this capability.

“This additional capability adds substantial value and progresses the sale of the company and PeriCoach system to a multinational”.

Quick facts: Analytica Ltd

Price: 0.004 AUD

ASX:ALT
Market: ASX
Market Cap: $14.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CardieX advances smart-wearable watch after recent agreement with Mobvoi...

Cardiex Ltd (ASX:CDX) chief executive officer and executive director Craig Cooper updates Proactive on latest developments with the company’s smart-wearable watch solution device following a recently announced development agreement with Mobvoi Information Technology. The CEO also provides an...

10 hours, 20 minutes ago

2 min read